Lv5
840 积分 2023-12-13 加入
Definitive local therapy for T4 prostate cancer associated with improved local control and survival
4天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
14天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
14天前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
20天前
已完结
Vascular mimicry developments in non-small cell lung cancer
21天前
已完结
Angiogenesis causes and vasculogenic mimicry formation in the context of cancer stem cells
21天前
已完结
Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects
21天前
已完结
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
21天前
已完结
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
21天前
已完结
Trends in the landscape of clinical trials of innovative drugs in China since 2015
25天前
已完结
皖公网安备34019202002308
